PI3K抑制剂在晚期乳腺癌中的疗效
本文综述PI3K/Akt通路在乳腺癌中的作用及PI3K抑制剂的研发历程。pan-PI3K抑制剂活性有限且副作用明显,而针对p110α亚型的alpelisib在内分泌 resistant、PIK3CA突变、HR阳性患者的大型随机试验中获批与氟维司群联用,疗效与安全性更优。文章还展望了未来联合治疗方向。
要点
- PI3K/Akt通路激活与内分泌耐药及不良预后相关,PIK3CA突变常见。
- pan-PI3K抑制剂活性有限且毒性限制使用。
- alpelisib联合氟维司群获批用于内分泌耐药PIK3CA突变HR阳性晚期乳腺癌。
核心结论
- alpelisib联合氟维司群获批用于内分泌耐药PIK3CA突变HR阳性晚期乳腺癌。
- 靶向p110α亚型较pan-PI3K抑制剂提供额外疗效和更好毒性特征。
研究设计与样本
- 本文为综述,总结PI3K抑制剂在乳腺癌中的主要研究并展望未来联合治疗。
主要发现
- PI3K/Akt通路激活与内分泌耐药和某些亚组预后更差相关,PIK3CA激活突变常见。
- pan-PI3K抑制剂显示一定活性但受限于副作用。
- 近期大型随机试验支持alpelisib联合氟维司群在内分泌耐药PIK3CA突变HR阳性肿瘤中的获批。
临床怎么用
- 对内分泌耐药PIK3CA突变HR阳性晚期乳腺癌可考虑alpelisib联合氟维司群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The phosphoinositide 3 (PI3)-kinase/Akt signaling pathway has always been a focus of interest in breast cancer due to its role in cell growth, cell proliferation, cell migration and deregulated apoptosis. Its activation has been linked to endocrine resistance and worse prognosis in certain subgroups of breast cancer. In addition, deregulation of the PI3K/Akt pathway including PIK3CA activating mutation is frequently present in breast cancer. Multiple efforts have been carried out to target this pathway, initially with pan-PI3K inhibitors with some hint of activity but hampered by their limiting side-effects. A recent large randomized trial in patients with endocrine-resistant PIK3CA-mutant hormone receptor (HR)-positive tumors led to the approval of the first PI3K inhibitor, alpelisib, in combination with fulvestrant. The specificity of alpelisib against the p110α catalytic isoform provided additional efficacy and a better toxicity profile. In this review, we summarize the main research with PI3K inhibitors in breast cancer and we provide some insight of potential future combinations of this treatment in breast cancer patients.
引用
- Verret B, Cortes J, Bachelot T, et al. Efficacy of PI3K inhibitors in advanced breast cancer. Ann Oncol. 2019. PMID: 31928690. doi:10.1093/annonc/mdz381
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。